Tick-Borne Encephalitis (TBE) is a rare, but potentially devastating disease affecting the brain and spine.1 Help your patients, particularly travelers to Europe and Asia who may be at risk of infection with tick-borne encephalitis virus (TBEV).2
Symptoms of TBE typically occur in 1/3 of those infected and can appear in 2 distinct phases.3 In the first phase, patients often present with flu-like symptoms of fever and headache while the second phase is characterized by central nervous system involvement with symptoms of meningitis.3 In rare cases, TBE viral infection can cause lifelong consequences, including disability and death.1,4
▼The CDC's Advisory Committee on Immunization Practices (ACIP) has unanimously voted to recommend the TBE vaccine for protection against TBE.5
For laboratory workers: TBE vaccination is recommended for those with a potential exposure to the TBE virus (TBEV).5
ACIP recommendations are provisional until published in the Morbidity and Mortality Weekly Report (MMWR).
TicoVacTM is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.6
Tick-borne Encephalitis is a disease caused by a virus that can be spread by a bite from an infected tick or through consumption of unpasteurized dairy products.2
Travelers spending time in wooded or grassy areas in many parts of Europe and Asia may be at risk for infection with tick-borne encephalitis virus (TBEV).2
TicoVacTM is >96% effective in preventing hospitalized TBE.6
TicoVacTM primary dosing series should be completed at least 1 week prior to potential exposure to TBEV.6
Ensure your patients have all the facts.
Already have a Pfizer Prime account?
Manage your account or place your order here.